Recent Updates — ATNM

Matt David, M.D., age 49, commenced service as Chief Financial Officer and principal financial officer of Actinium Pharmaceuticals on October 14, 2026. He joins from CorMedix Inc., where he served most recently as Executive Vice President and Chief Business Officer after previously holding the CFO role. Under his offer letter, Dr. David receives an annual base salary of $450,000, a target performance bonus of 40% of base salary, and a $150,000 sign-on bonus. He was also granted 250,000 stock options and 325,000 restricted stock units under the Company’s 2026 Employment Inducement Award Plan. The awards vest over four years with performance-based conditions tied to corporate milestones. Actinium Pharmaceuticals is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer.

Actinium Pharmaceuticals received acceptance of its compliance plan from NYSE Regulation, granting a maximum extension period through November 27, 2027, to regain compliance with listing standards regarding minimum bid price and shareholder equity. The company's common stock will continue trading on NYSE American under the symbol ATNM during this period, subject to periodic reviews of its progress. Concurrently, Actinium announced intellectual property advances for its Actimab-A program, including newly issued US patents for solid tumor treatments and pre-grant status for AML combination therapies. The company also expanded manufacturing capacity by adding a second supplier for Actimab-A to support upcoming clinical milestones in the second half of 2026 and throughout 2027. Actinium Pharmaceuticals is a biopharmaceutical company developing targeted radiotherapies for cancer treatment.

Actinium Pharmaceuticals, Inc. submitted a compliance plan to NYSE American on June 18, 2026, to address non-compliance with stockholders' equity requirements. The company was notified on May 27, 2026, that it failed to maintain the minimum $4.0 million stockholders' equity threshold required by the exchange. Actinium Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing radiopharmaceuticals for cancer treatment.